Thinly traded nano cap ContraVir Pharmaceuticals (CTRV +21.4%) is up average volume in early trade in apparent response to just-published research on cyclophilin inhibitor CRV431 in a mouse model of hepatitis B (HBV).
The data, appearing in PLOS ONE, showed that CRV431 significantly reduced HBV DNA in the liver of transgenic mice in a dose-dependent manner while also reducing serum levels of surface antigen (HBsAg) (surface antigen signifies an active infection).
CRV431 is currently in Phase 1 development.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.